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Background: Mechanical heart valves carry significant risk during pregnancy.
Aim: To assess the risk of pregnancy and delivery for mother and child in women with
mechanical heart valve prosthesis.
Methods: Multicenter retrospective observational study of women with mechanical heart
valve prosthesis. The regimen with low molecular weight heparin throughout pregnancy
(LMWH) was compared to warfarin since the second trimester (W).
Results: Out of 419 pregnant women with cardiovascular diseases we assessed 14 women with
mechanical heart valve prosthesis (3.3%) who experienced 23 pregnancies. There were 13
pregnancies with aortic valve prosthesis, 8 with prosthesis of atrio-ventricular valves and 2
pregnancies with both aortic and mitral valve prosthesis. LMWH regimen was used in 18
pregnancies, W in 5 pregnancies. Major maternal complications occurred in 65% of
pregnancies, including 3 strokes and 3 urgent cardio-surgical procedures, all in women with
LMWH regimen. Prosthetic valve thrombosis occurred in 26%, all in the LMWH group; no
thrombosis was found in W group, (p¼0.166). Major bleeding occurred in 30% with no
difference between LMWH and W groups (p¼0.596). Fetal loss represented 26% of all
pregnancies with no difference between LMWH and W group (p¼1). The birth weight was
not significantly different between LMWH andW groups (24967327 g vs. 31327592 g, p¼0.12).ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
alth, Czech Republic) for conceptual development of research organisation 00064203).
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Table 1 – Data from specialised centers
Centre Women
with
CHD
Pregnant women
cardiovasc. dises
Homolka,
Praha
1352 193
Bohunice
Brno
602 203
FN Hradec
Kra´love´
354 11
FN
Olomouc
18 12
FN Plzenˇ ? ?
VFN
Praha
? ?
FN Motol 384 ?
altogether 2710 419
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 1 7 – e 2 2 2e218Conclusion: The rate of maternal and fetal complications in pregnant women with mechanical
valve prosthesis is still high. The anticoagulation regimen using warfarin since the second
trimester appears to be the safest one. The best prevention of complications is to avoid the
implantation of mechanical valve prosthesis in girls and women in fertile age.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
.Mechanical heart valves carry significant risk during pregnancy
due to the risk of thrombosis of the prosthetic valve with
possible embolisation or heart failure on one hand and the risk
of bleeding on the other hand. There is also a fear of the
possible embryopathy caused by oral anticoagulants, especially
in the first trimester. The options of different anticoagulation
regimens during pregnancy are not proved by controlled ran-
domised clinical studies [1,2]. The assessment of the complica-
tions during pregnancy with mechanical heart valve is
extremely important, because there are more surgical options
nowadays on how to avoid implantation of mechanical valve
prosthesis in girls or women in fertile age.
Nowadays we can hardly find rheumatic valve disease in
young people in our country. The most frequent reasons for
the implantation of mechanical heart valve prosthesis are
congenital heart diseases (CHDs) and infective endocarditis,
which may accompany even mild congenital heart abnorm-
alities, such as bicuspid aortic valve or mitral valve prolapse.1. Aim
The aim of our study was to assess the risk of pregnancy and
delivery in women with mechanical heart valve prosthesis
with different anticoagulation regimens.2. Methods
We retrospectively assessed the course of pregnancy and
delivery in women with mechanical heart valve prosthesis
during the last 5 years. The data were collected from the
databases of 3 specialised tertiary referral Centres for adultsfor adults with congen
with
ase
Women in fert
mechanical pr
57
10
26
2
9
?
?
104with congenital heart diseases and from 4 other Cardiovas-
cular centres in University hospitals in different regions of
the Czech Republic. We evaluated the type of the heart
disease, other important diagnoses, type and position of the
prosthesis, anticoagulation treatment and it’s monitoring
during pregnancy, mode of delivery, cardiovascular complica-
tions, obstetrical and newborn complications and the rate of
abortions and fetal death.
To compare the results between two groups the unpaired T-
test, chi-square test and Fisher’s exact test were used for
categorical variables. Significant difference was considered
for po0.05.3. Results
We assessed altogether 23 pregnancies in 14 women with
mechanical heart valve prosthesis. Most pregnant women
with mechanical prosthesis were found in the databases of
the specialised Centres for adults with congenital heart
diseases (Table 1). The average age at the time of the first
pregnancy was 30.375.3 years.
Nine pregnant women had aortic valve prosthesis. The
reason for implantation was severe regurgitation or stenosis
on bicuspid aortic valve (5x), infective endocarditis (IE) on
bicuspid aortic valve (2x), rheumatic aortic stenosis in one
women coming from Asia (1x). One woman with congenital
aortic stenosis and IE had both aortic and mitral mechanical
valve prosthesis, she also had Leiden mutation. Four women
had mechanical mitral valve prosthesis, 2 of them due to
residual mitral regurgitation after the operation of incomplete
atrio-ventricular septal defect (AVSD) in childhood, 2 due to IE.ital heart disease and other cardiovascular centers.
ile age with
osthesis
Pregnant women with
mechanical prosthesis
Pregnancies with
mechanical
prosthesis
8 11
2 4
1 1
1 1
1 4
1 2
0 0
14 23
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 1 7 – e 2 2 2 e219One woman with congenitally corrected transposition of the
great arteries had mechanical atrio-ventricular valve in the
systemic right ventricle, one woman with Ebstein anomaly had
mechanical valve in tricuspid position. Altogether there were 9
women (15 pregnancies) with mechanical valve in the aortic
position (high pressure system) and 6 women (10 pregnancies)
with mechanical heart valve in mitral or tricuspid position (low
pressure system). Out of them one woman had both aortic and
mitral prosthesis and 2 pregnancies. All but one prosthesis were
bileaflet, one mitral prosthesis was tilting disc.
The anticoagulation regimen comprised low molecular
weight heparin throughout the whole pregnancy (LMWH) in
18 pregnancies (78%), in 2 of them in combination with a low
dose of acetylosalicylic acid (50–80 mg). Warfarin (W) was
used in 5 pregnancies since the 13th week of pregnancy withTable 2 – Complications in women with mechanical
heart valve prosthesis during pregnancy and after
delivery.
No. of
pregnancies
(altogether 23)
% of
pregnancies
Major maternal
complications
15 65
Stroke 3 13
Valve thrombosis 6 26
Cardiac surgery before or
immediately after delivery
3 13
Bleeding with the need of
transfusion or revision
7 30
Fetal death/abortion 6 26
Table 3 – Complications in pregnancy according to mechanica
Complications
High pressure system - aortic
Thrombosis
Bleeding
Fetal loss
Low pressure system - mitral, tricuspid, CCTGA
Thrombosis
Bleeding
Fetal loss
LMWH: Low molecular weight heparin throughout pregnancy.
Warfarin: LMWH in the week 6–12 and before delivery, otherwise warfar
CCTGA: Congenitally corrected transposition of the great arteries with
ventricle.
NS: Not significant.
n One woman had both aortic and mitral mechanical valve prosthesis a
Table 4 – Pregnancies with warfarin (W) regimen (N¼5).
No. Prosthesis site Daily dose of w (mg) INR
1 Mitral 12.5 3.5
2 CCTGA 7.5 2.9
3 Aortic 4.5 ?
4 Aortic 10 2
5 Aortic 4.5 2–3frequent assessment of INR. Women treated by W used
LMWH with the assessment of antiXa in the first trimester
and before delivery.
There were 17 live-born children out of 23 pregnancies
(74%). Most deliveries were performed by Caesarean section
(88%); there were only 2 planned vaginal deliveries. No
embryopathy was referred, 1 baby had a congenital aortic
valve disease.
There was no maternal mortality. However, the rate of
maternal complications was high. We found only 3 women
out of 14 (21%) without maternal complications. Major maternal
complications occurred in 65% of pregnancies (Table 2).
There were 6 valve thromboses (26%) among 23 pregnan-
cies. All thrombosis developed during the treatment with low
molecular weight heparin (LMWH), 5x due to inadequate dose
of the LMWH with low antiXa, 1x with adequate dose of
LMWH with antiXa (0.8 IU/ml). No valve thrombosis occurred
among 5 pregnancies treated by warfarin since the second
trimester (p¼0.166), (Table 3, Table 4, Table 5).
Three women experienced valve obstruction requiring acute
cardiac surgery during pregnancy (13% of pregnancies), another
three valve thrombosis were treated conservatively with
heparin or thrombolysis. Three women had ischemic stroke
due to valve thrombosis during pregnancy or after delivery.
Gynaecological bleeding requiring transfusion or revision
appeared in 7 pregnancies out of 23 (30%), (Table 2). It was
present in 2 out of 5 pregnancies treated by warfarin (40%), in
2 out of 2 (100%) of those treated by LMWH with low dose of
aspirin (ASA), and in 3 out of 16 pregnancies treated by
LMWH only (19%), (Table 5). There was no significant differ-
ence in major bleeding between LMWH and W groups
(p¼0.596).l valve position and anticoagulation regimen.
LMWH No. of pregnancies Warfarin No. of pregnancies p
12 3
3 (25%) 0 NS
3 (25%) 1 (33%) NS
1 (8%) 0 NS
8 2
3 (37.5%) 0 NS
2 (25%) 1 (50%) NS
4 (50%) 1 (50%) NS
in.
mechanical valve in atrio-ventricular position in the systemic right
nd 2 pregnancies, the real number of pregnancies was 23.
Thrombosis Bleeding Stroke Fetal loss
– – – 1
– 1 – –
– – – –
– – – –
– 1 – –
Table 5 – Pregnancies with low molecular weight heparin (LMWH) regimen (N¼18).
No. Prosthesis site Daily dose of LMWH (ml) Anti-Xa Thrombosis Bleeding Stroke Fetal loss
1 Mitral 2 1 ml 0.62–0.69 – – – 1
2 Mitral 2 1 mlþASA 50 0.79 – 1 – –
3 Mitral 1 ? ND 1 – – 1
4 Mitral 2 0.8 mlþASA 80 ND – 1 – –
5 CCTGA 1 0.6 ml 0.4 1 – – 1
6 Ebstein 2 0.8 ml ND – – – 1
7 Mitralþaortic 2 0.4 ml ND – – – –
8 Mitralþaortic 2 0.4 ml 0.41 1 – 1 –
9 Aortic 2 0.8–1 ml 0.8 1 – 1 –
10 Aortic 2 0.6 ml 0.84–0.78 – 1 – –
11 Aortic 2 0.6 ml 0.52–0.78 1 1 1 –
12 Aortic ? ? – – – 1
13 Aortic 2 0.7 ml 0.88 – – – –
14 Aortic 2 1 ml 0.87 – 1 – –
15 Aortic 2 0.6 ml 0.1 1 – – –
16 Aortic ? ? – – – –
17 Aortic ? ? – – – –
18 Aortic ? ? – – – –
LMWH: Low molecular weight heparin throughout pregnancy.
W: (warfarin)¼LMWH in the week 6–12 and before delivery, otherwise warfarin.
CCTGA: Congenitally corrected transposition of the great arteries with mechanical valve in atrio-ventricular position in the systemic right
ventricle.
ASA: Acetylosalicylic acid (mg).
ND: Not done.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 1 7 – e 2 2 2e220Fetal loss or abortion occurred in 6 pregnancies out of 23
(26%). All but one were in women treated by LMWH. We did
not find any significant difference in fetal loss between the
groups treated by LMWH and warfarin (25% vs. 20%, p¼1).
There were two spontaneous abortions in the first trimester,
2 fetal deaths in the second trimester and 2 fetal losses as the
probable consequence of cardiac surgery due to valve
obstruction. The average birth weight in the ‘‘warfarin’’ and
‘‘LMWH throughout pregnancy’’ groups was 31327592 g and
24967327 g, p¼0.12.4. Discussion
Low molecular weight heparin has a stable place in the
prevention of thromboembolic events; it can replace warfarin
before surgery or before other interventions. Because of no
harmful effect to fetus it is often used in pregnancy in
different indications. However, the use of LMWH for pregnant
women with mechanical valve prosthesis is not recom-
mended by the latest guidelines because of the risk of
thrombosis [1].
Although the maternal mortality was zero in our study, the
rate of complications was surprisingly high. Almost 80% of all
pregnant women with mechanical heart valve prosthesis
experienced some kind of maternal complications (at least
during one pregnancy), including three urgent cardiac surgi-
cal procedures and three strokes.
Thrombosis of the mechanical valve prosthesis during pregnancy
was found in 26% of all pregnancies. Valve thrombosis was
detected only in those women treated by LMWH throughout
pregnancy. No prosthesis thrombosis was found in women
treated by warfarin from the second trimester. The smallnumber of women in the warfarin group is probably responsible
for the fact, that the difference between the groups was not
significant. Very similar rate of mechanical valve thrombosis
33% was found in a large review of literature in the ‘‘heparin
through pregnancy’’ group [2]. The reason for valve thrombosis
in our study was inappropriately low dose of LMWH in all but
one patient. In one woman the thrombosis developed during
well controlled LMWH treatment with antiXa 0.8 IU/ml. Similar
results with thrombotic complications mostly due to sub-
therapeutic antiXa levels were referred also by other authors
[3]. However, the risk of valve thrombosis was not excluded
even with reaching the therapeutic levels of antiXa, similarly to
our experience [4,5]. There is a discussion, if the measurements
of the pre-dose levels were helpful, with the recommended
level of 0.6–0.7 IU/ml [6].
Three surgically treated valve thrombosis in our series
resulted in 2 fetal loss. Three valve thrombosis resulted in
ischemic cerebral stroke. Even if the difference between the
two anticoagulation regimens was not significant due to the
small numbers, all valve thrombosis with the subsequent
complications were found in the LMWH group, none was in
the warfarin group. Our results support the hazard of giving
LMWH throughout the pregnancy, in agreement with the new
European guidelines [1].
The rate of women treated by LMWH throughout preg-
nancy was surprisingly high (78%) in our retrospective study.
It may be partly explained by the lack of clear information in
the previous years. Many cardiologists still historically over-
estimate the danger of warfarin in pregnancy and under-
estimate the LMWH risk. The broad use of LMWH in other
situations and also in pregnant women without mechanical
prosthesis may contribute to the explanation of the LMWH
preference.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 1 7 – e 2 2 2 e221The rate of maternal bleeding requiring transfusion or surgical
revision represented 30% of pregnancies in our study. Similar
rate of haemorrhagic complications (17% antenatal and 32%
postnatal) were found by other authors [3]. The addition of
low-dose aspirin (75–100 mg) to anticoagulation therapy is
recommended in high risk patients with mechanical heart
valves also in pregnancy, in the second and third trimester,
especially in the USA [7,8]. In our study we used the
combination of LMWH with low dose of ASA in two women
with older types of mitral prosthesis and left ventricular
dysfunction. However, both women had bleeding, one of
them required hysterectomy after delivery. Using the combi-
nation of ASA with anticoagulation we must be aware of the
higher risk of bleeding. The other haemorrhagic complica-
tions occurred in peripartum while women were on LMWH
only. The risk of bleeding could be decreased with the stop of
aspirin one week before planned delivery and the use of
postpartum intravenous unfractionated heparin (UFH) with
aPTT controls until warfarin reaches the therapeutic level.
The UFH can be fully reversed by protamin unlike that
of LMWH.
Warfarin embryopathy was not found in our study. However,
we had no women treated by warfarin between the weeks
6–12. In 5 pregnancies from our series warfarin has been
given since the 13th week and was controlled by INR.
Warfarin embryopathy is described in the literature in 6.4%
of women treated with warfarin throughout the pregnancy,
while heparin given from the 6th to the 12th week eliminates
this risk substantially [1,2]. The lower dose of warfarino5 mg
carries lower risk of embryopathy (2.6%), [1]. There was only
one bleeding and one fetal loss in our warfarin group without
any valve thrombosis or stroke.
The rate of fetal loss was 26% in our series, without sig-
nificant difference between LMWH and warfarin groups. Our
results are in contradiction with another study, where the
fetal loss was 70% in women treated by warfarin and 25% in
heparin-treated women [9]. However, the numbers in our
study are small.
The rate of Caesarean sections was high in our study,
mostly due to obstetrician decision. However, vaginal delivery
is contraindicated in women treated by warfarin.
The small number of pregnant women with mechanical
valve prosthesis (3.3%) in our relatively large series of 2710
women with CHD may be explained by the increasing trend
in valve sparing operations of the aortic and mitral valve
and also increasing use of bioprosthesis or Ross procedure
for women in fertile age. Every effort should be taken to
avoid mechanical prosthesis in women who are planning
pregnancy.
In conclusion, warfarin seems to be safe concerning valve
thrombosis, but it has the risk of embryopathy in the first
trimester, especially if the daily dose exceeds 5 mg. It may
have a higher rate of fetal loss and stillbirths [9], which was
not confirmed by our experience. LMWH throughout preg-
nancy has definitely a high risk of valve thrombosis, which
can be only partly eliminated by keeping the target antiXa.
Bleeding complications can be expected in a similar rate in
both regimens.
The management of pregnant women with mechanical
valve prosthesis is one of the most challenging and difficultsubjects. The suggestion of the safest management for
mother and child provoked many controversial discussions
and even nowadays the recommendations may differ
because of the lack of randomised studies. Most data come
from smaller observational studies [1–3]. The recommenda-
tions in the older guidelines are insufficient [10].
4.1. The current recommendations
The new guidelines of the European Society of Cardiology
provide the following recommendations [1]: Oral anticoagulant treatment should be continued until
pregnancy is achieved. Continuation of oral anticoagulants should be considered
if the dose of warfarin is less than 5 mg a day with a
weekly control of INR. If the daily dose of warfarin is higher or the mother is not
willing to accept a small risk of embryopathy (less than
3%), warfarin is replaced by UFH or LMWH in the weeks
6–12 with the proper control and dose adjustment
(aPTT42x in UFH or antiXa 0.8–1.2 IU/ml in LMWH 4–6 h
after the application weekly). The importance of the pre-
dose level of antiXa above 0.6 IU/ml has not been studied
sufficiently. Planned delivery is preferred.
 Because of the risk of fetal hemorrhage, warfarin should
be withdrawn 2–4 weeks before delivery and switched to
heparin or LMWH Delivery should take place in a tertiary centre
 Vaginal delivery is recommended for women with good
function of the heart and valves, without dilatation of the
aorta, who take heparin or LMWH Vaginal delivery is contraindicated in women taking war-
farin because of the risk of fetal intracranial bleeding Planned Caesarean section may be considered for patients
with a high risk of valve thrombosis in order to keep the
time without warfarin as short as possible [1] The combination of anticoagulation therapy with low dose
of ASA (75–100 mg) in the second and third trimester is
recommended by the ACC/AHA guidelines [7]. It decreases
the risk of thrombosis in high-risk patients, but increases
the risk of bleeding.
Our results confirm the abovementioned strategy. However,
the best strategy for the future seems to avoid the implanta-
tion of the mechanical valves to girls and women in fertile
age. If the mechanical valve has already been implanted,
these women should get detailed information about the risks
of pregnancy and principles of anticoagulation therapy.5. Limitations of the study
The number of pregnancies with mechanical valve prosthesis
is too low to perform a valuable statistical analysis between
the groups with different anticoagulation regimens and
different valve position.
The main limitation of our study is that we were probably
not able to include all pregnant women with the mechanical
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 1 7 – e 2 2 2e222heart valve prostheses. We admit there could be a selection
bias. The women with uncomplicated pregnancy with
mechanical valve prosthesis could have been followed by
their local cardiologist and the delivery could have taken
place in a local maternity hospital, whereas the complicated
or risky patients were more likely to be sent to the centres.
However, we checked the databases of specialised centres for
adults with congenital heart diseases as well as non-specia-
lised large cardiological centres in different regions of our
country. We also asked maternal departments and several
local cardiologists, but they were not able to provide us with
the data because of the lack of database system. The
database of pregnant women with mechanical heart valve
prosthesis would be certainly useful. Even with the above-
mentioned limitations the results are warning.6. Conclusion
In spite of regular cardiological controls, we found a high rate
of maternal and fetal complications in pregnant women with
mechanical heart valve prosthesis. The difference between
preventive and therapeutical anticoagulation in pregnancy
should be emphasized. The appropriate anticoagulation regi-
men with frequent controls of anticoagulation activity and
dose adjustment is needed. The strategy with LMWH in the
first trimester and warfarin since the second trimester seems
to be safer with better results than LMWH throughout the
whole pregnancy. The best prevention of the complications is
to avoid the implantation of mechanical heart valves in girls
and women in the fertile age.
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